Company profile: Nkarta
1.1 - Company Overview
Company description
- Provider of a cell engineering platform for next-generation cell therapies, offering allogeneic off-the-shelf CAR-NK treatments including NKX101, an NKG2D CAR-NK for hematologic malignancies and solid tumors, and NKX019, a CD19-targeting CAR-NK for B-cell malignancies, supported by a proprietary allogeneic manufacturing process for NK cell collection, activation, engineering, expansion, and cryopreservation.
Products and services
- Allogeneic Manufacturing Process: Proprietary workflow that collects, activates, engineers, expands, and cryopreserves NK cells, enabling off-the-shelf therapeutic use
- NKX019: CAR-NK, CD19-targeted cell therapy that engineers NK cells to recognize CD19 on B‑cell malignancies and is built for treatment of B‑cell cancers
- NKX101: Allogeneic off-the-shelf NKG2D CAR‑NK therapy that engineers NK cells for treatment of various hematologic malignancies and solid tumors, harnessing NKG2D‑directed targeting
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Nkarta
CarThera
HQ: France
Website
- Description: Provider of therapeutic ultrasound-based medical devices for treating brain disorders, including SonoCloud, an intracranial implant that uses low-intensity pulsed ultrasound to temporarily open the blood-brain barrier for enhanced delivery of therapeutic agents, and SonoCloud-9, a nine-emitter version to open larger regions; also conducts preclinical and clinical R&D combining SonoCloud with therapeutic agents to treat brain tumors and neurodegenerative diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CarThera company profile →
Morphic Therapeutics
HQ: United States
Website
- Description: Provider of oral integrin therapies in development to treat serious chronic diseases, including autoimmune, cardiovascular, and metabolic diseases, fibrosis, and cancer; developing treatments for patients with immunological, fibrotic, neoplastic, and vascular diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Morphic Therapeutics company profile →
Viventia Bio
HQ: Canada
Website
- Description: Provider of next-generation oncology therapeutics utilizing proprietary Targeted Protein Therapeutic (TPT) technology; a privately held biopharmaceutical company focused on the discovery and development of TPT-based product candidates with potential advantages in treating cancer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Viventia Bio company profile →
Immunicum
HQ: Sweden
Website
- Description: Provider of clinical phase II cancer immunotherapies, including therapeutic cancer vaccines and T-cell expansion methods rooted in transplantation immunology. Offerings include Vididencel, a maintenance therapy for measurable residual disease in AML and ovarian cancer; Ilixadencel, an intratumoral immune primer of pro-inflammatory donor dendritic cells for combination treatment of hard-to-treat solid tumors; and a preclinical memory NK-cell expansion platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Immunicum company profile →
IsoPlexis
HQ: United States
Website
- Description: Provider of single-cell detection technology that identifies a wide range of patient immune responses at the single-cell level. Its platform assesses the safety and efficacy of therapeutics and monitors disease progression to support improved therapeutic development and inform physician decisions.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full IsoPlexis company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Nkarta
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Nkarta
2.2 - Growth funds investing in similar companies to Nkarta
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Nkarta
4.2 - Public trading comparable groups for Nkarta
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →